Analytical interference caused by pre-analytical factors is the main source of error in clinical laboratory measurements. Hemolysis, icterus and lipemia commonly interfere with spectrophotometric methods. Currently, the new chemistry analyzers can measure these three serum indices before chemistry test quantification [1, 2] . This measurement is carried out at zero reagent cost to all samples that are processed in order to study possible interferences.
To the Editor, Analytical interference caused by pre-analytical factors is the main source of error in clinical laboratory measurements. Hemolysis, icterus and lipemia commonly interfere with spectrophotometric methods. Currently, the new chemistry analyzers can measure these three serum indices before chemistry test quantification [1, 2] . This measurement is carried out at zero reagent cost to all samples that are processed in order to study possible interferences.
Total bilirubin (TBIL) in serum determination is a widely requested parameter to evaluate the hepatobiliary function [3] . Although the test is not excessively expensive, a high number of inappropriate test requests throughout the year means a significant annual cost to the laboratory.
Usually, the icteric index (ICTI) is not used for the quantitative determination of TBIL. However, it seems that it could help to detect abnormal TBIL values and to decide whether its quantification is worthwhile has not yet been evaluated [4] . Besides, results of ICTI could be a useful tool for detecting hyperbilirubinemia in patients when measurement of TBIL is not ordered. The implementation of reflex testing and algorithms could improve the test request and correct the overuse and the misuse of tests [5] .
For these reasons, the aim of our study was to evaluate the ICTI as a screening biomarker for abnormal TBIL results.
This research was carried out at Laboratori Clínic L'Hospitalet of Primary Health Care of Catalan Institute of Health.
Data from the laboratory information system from January 2017 to December 2017 were analyzed for this retrospective study. Samples selected for the analysis were those for which measurement of both TBIL and ICTI was requested. Test results were obtained from the laboratory database (OMEGA 3000; Roche Diagnostics, Barcelona, Spain) using data warehouse-base software (OMNIUM; SunSet Technologies, Girona, Spain). To evaluate the previous results in a different study, a prospective 1-month study (January 2018) was performed in a separate population.
TBIL and ICTI were measured on Cobas8000 c702 (Roche Diagnostics) using manufacturer's reagents. TBIL was measured by molecular absorption spectrometry using diazonium (600 nm and 546 nm). The serum index assay is based on calculations of absorbance measurements of diluted samples (0.9% sodium chloride) to provide semi-quantitative results: hemolysis (570 nm and 600 nm) (A 1 ), lipemia (660 nm and 700 nm) (A 2 ) and icterus (480 nm and 505 nm) (A 3 ). From these absorbance values, the instrument calculates serum index values using the formula shown in Table 1 .
We considered that TBIL test results were the gold standard and we defined jaundice when the total serum bilirubin concentration was >18 μmol/L. Linear regression analysis, correlation coefficient and receiver operating characteristic (ROC) curve analysis were performed. The diagnostic accuracy of ICTI was determined by sensitivity, specificity, positive (LR+) and negative (LR−) likelihood ratios, positive predictive value (PPV) and negative predictive value (NPV). Data are presented with exact 95% CI.
A cost-effectiveness study of the implementation of the ICTI cut-off found was performed: if the ICTI values were lower than the cut-off, the TBIL test will not be performed. The TBIL test would automatically be requested when the ICTI was higher than or equal to the cut-off. The cost of the serum bilirubin determination was €0.21 (cost established by the Catalan Health Institute).
Statistical calculations were performed using STATA 12.0 software. The study collected 185,791 samples with TBIL and ICTI results in 2017. Linear regression analysis was y = 1.058 × (95% CI: 1.056-1.059) + 5.072 (95% CI: 5.055-5.089). The correlation coefficient (R 2 ) was 0.995.
The ROC curve analysis shows that the most accurate ICTI cut-off value to discriminate jaundice was ≥21. The area under the curve was 0.9957 (95% CI: 0.9954-0.9959). The sensitivity, specificity, PPV, NPV, LR+ and LR− of ICTI for the detection of TBIL values above 18 μmol/L are shown in Table 2 .
LR values indicate that ICTI ≥ 21 increases 13.52-fold the probability of jaundice and a negative ICTI (ICTI < 21) significantly decreases 0.0016-fold the probability of jaundice. Analysis of false-negative results showed a median (min-max) TBIL of 19 (19-29) μmol/L with ICTI 20 (10-20). False-positive results showed a median (min-max) TBIL of 15 (3-18) μmol/L with ICTI 22 (21-42). The ICTI cut-off for 100% sensitivity is ≥10 and for 100% specificity is ≥36. The cost-effectiveness study applying the ICTI ≥ 21 shows that we would have saved 163,100 TBIL tests and €34,251 per year.
During the prospective 1-month study, there were 40,745 samples with ICTI done. Applying ICTI ≥ 21 as a cut-off, there were 4050 samples that required the measurement of TBIL (9.9%). Instead, the laboratory performed 17,030 TBIL measurements. There were 15,148 requested tests with negative results (88.9%) and 1882 requested tests with positive results. There were 2168 samples with ICTI ≥ 21 without a TBIL test ordered for which it would not have been performed.
There are few studies to show the use of the ICTI as a screening test for the identification of blood samples with abnormal TBIL concentrations [6, 7] . Our findings could contribute further evidence to Salinas et al. [6] and Szoke et al. [7] results, even if obtained with instruments of different Roche Diagnostic series (Cobas 8000-c702).
The diagnostic accuracy results of our study show the excellent correlation between the ICTI and TBIL results. Looking at coefficients of determination, our results are better than those of Salinas et al. [6] and Szoke et al. [7] .
Our study concludes that when the ICTI is ≥21, TBIL should be measured. The 99.86% of patients with ICTI is ≥21 will have TBIL values above the reference range (>18 μmol/L). The rate of false-negative results (0.007%) was minimal compared with that in the literature [6, 7] . This supports that ICTI is a powerful biomarker to discard the measurement of TBIL when values are less than 21. False positives (7.0%) were more frequent in our study than in Szoke et al.'s (5.1%) and Salinas et al.'s (1.2%) studies because our ICTI cut-off is lower than that reported in the literature (ICTI ≥ 34.2) [6, 7] .
This study shows how this screening tool would have resulted in economic savings. The implementation of this strategy in our primary care laboratory in a 1-year period would have achieved a saving of €34,251. Although the TBIL test is not excessively expensive, a high number of inappropriate test requests throughout the year means a significant annual cost to the laboratory. The application of this algorithm improves circuits in large laboratories and reduces the turnaround times. Laboratory professionals should promote the appropriateness of test request.
The prospective study carried out has saved 15,148 TBIL tests with negative results and most importantly, we found 2168 TBIL tests in patients that had never been performed.
The implementation of this strategy should be planned by laboratory professionals and discussed with requesting physicians, according to the laboratory information system. This is the first application of the ICTI for diagnostic purposes. It is worth keeping in mind that hemolysis, icteric and lipemic indices measured automatically are only semi-quantitative tests aimed to assess sample quality as indicators of interference. 
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D: sample dilution-dependent and unit-dependent scaling factors to provide semi-quantitative interference levels. A 1,2,3 : dichromatics absorbances obtained at 700 and 660 nm for hemolysis, lipemia and icterus. E, F: correction of the measurement of bilirubin A 3 for hemoglobin and lipemia. Correcting factors which correct overlapping interference spectra are independent of sample dilution as they are based on ratios of absorbances.
